Niclas Högberg and William ‘Obi’ Greenman on Evolving Strategies in Massive Bleeding Management
Niclas Högberg, Sales Director at Cerus, reposted from William “Obi” Greenman on LinkedIn:
”MASSIVE BLEEDING – ARE WE DRIFTING APART IN STRATEGY?
In the U.S., 5-day Pathogen-Reduced Cryoprecipitated Fibrinogen Complex (PRCFC) is beginning to reshape massive transfusion practice.
As the study included concluded:
- “PRCFC is ready to dispense and provides an immediate source of fibrinogen in critically bleeding patients with significant reductions in TAT. There is an added benefit of reduced wastage.”
This evolution enables clinicians to act within minutes — moving beyond ratio-driven MTPs toward targeted, function-based hemostatic resuscitation.
Across Europe and the Nordics, focus has instead shifted toward Whole Blood (WB) for trauma and pre-hospital use.
While physiologically balanced, WB reintroduces challenges with traceability, shelf life, and pathogen safety — factors that SoHO and IVDR will soon regulate more tightly.
As Europe strengthens its blood preparedness and resilience, the key question is:
- Are we innovating forward — or reinventing the past for convenience?”
William “Obi” Greenman, Chairman and Chief Executive Officer at Cerus, shared on LinkedIn:
”The expansion of INTERCEPT Fibrinogen Complex use in large U.S. hospitals is really encouraging given the meaningful impact on immediate fibrinogen delivery in critically bleeding patients.
With >50% improvements in delivery time and reduced wastage, the efficiencies gained are real and the hospital transfusion service teams love the product and can focus their valuable time on other critical activities.”
Read the full article here.
Article: Pathogen-reduced cryoprecipitate: Early experiences and inventory management
Authors: C. B. Webb, A. Javanbakht, D. Hanna, S. G. Yates, R. Zhang, S. Afraz, R. Sarode

Stay updated on all scientific advances with Hemostasis Today.
-
Jul 13, 2026, 23:39Yaariv Khaykin: Whole-Person Care Can Strengthen Stroke Prevention in Patients With Atrial Fibrillation
-
Jul 13, 2026, 22:33ESOC 2026 recordings are now available on eSTEP – European Stroke Organisation
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026